Correlation study evaluated the efficacy of neoadjuvant chemotherapy for non small cell lung cancer
-
摘要: 术前新辅助化疗已成为非小细胞肺癌患者的标准化治疗方案,随着新辅助化疗在临床治疗中的广泛应用,疗效评价显得尤为重要。如何能无创、及时、准确、有效的评价化疗疗效已成为临床研究的重点。目前临床上通常采用影像学及病理学检查等方法,同时对非小细胞肺癌生物学因子的研究也在迅速开展。现将各种评价方法的应用现状作一综述。Abstract: Preoperative neoadjuvant chemotherapy has become the standard treatment for patients with non small cell lung cancer, with the wide application of neoadjuvant chemotherapy in clinical treatment, curative effect evaluation is very important. How can a noninvasive, accurate, timely, effective chemotherapy efficacy evaluation has become the focus of clinical research. Current clinical commonly used imaging and histopathological examination method, while the study of non small cell lung cancer biology factor also in rapid development. We will make a review on the application status of various evaluation methods.
-
[1] Zou XN, Lin DM, Wan X, et al. Histological subtypes of lung cancer in Chinese males from 2000 to 2012[J]. Biomed Environ Sci, 2014, 27(1): 3-9. [2] Mountain CF. Revisions in the international system for staging lung cancers[J]. Chest, 1997, 111(6): 1486-7. doi: 10.1378/chest.111.6.1486 [3] Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 87(12): 881-6. [4] James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement [J]. J Natl Cancer Inst, 1999, 91(6): 523-8. doi: 10.1093/jnci/91.6.523 [5] Padhani AR, Ollivier L. Commentary - the RECIST criteria: implications for diagnostic radiologists[J]. Br J Radiol, 2001, 74 (887): 983-6. doi: 10.1259/bjr.74.887.740983 [6] Hellomi M, Petralia G, Sonzogni A, et al. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma:initial experience[J]. Radiology, 2007, 244(2): 486-93. doi: 10.1148/radiol.2442061189 [7] Ng QS, Goh V, Fichte H, et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements[J]. Radiology, 2006, 239(2): 547-53. doi: 10.1148/radiol.2392050568 [8] Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology[J]. Acad Radiol, 2000, 7 (10): 840-50. doi: 10.1016/S1076-6332(00)80632-7 [9] Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis[J]. Q J Nucl Med, 2003, 47(3): 171-87. [10] Wang GL, Zhang CQ, Li MY, et al. Preliminary application of High-Definition computed tomographic gemstone spectral imaging in lung cancer[J]. J Comput Assist Tomogr, 2014, 38(1): 77-81. doi: 10.1097/RCT.0b013e3182a21633 [11] Mazzei MA, Guerrini S, Genovese EA, et al. Accuracy of multislice CT in restaging patients with non-small cell lung carcinoma after neoadjuvant chemotherapy using a multiparametric approach[J]. Recenti Prog Med, 2012, 103(11): 465-70. [12] Kamiyoshihara M, Kawashima O, Ishikawa S, et al. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer[J]. J Cardiovasc Surg (Torino), 2001, 42(1): 119-24. [13] Shiau YC, Hsieh JF, Tsai SC, et al. Technetium-99m methoxy-isobutyl-isonitrile chest single photon emission computed tomography to detect mediastinal lymph node metastasis in patients with non-small cell lung cancer: comparison with computed tomography[J]. Anticancer Res, 2001, 20(5C): 3751-4. https://www.researchgate.net/publication/12065487_Technetium-99m_methoxy-isobutyl-isonitrile_chest_single_photon_emission_computed_tomography_to_detect_mediastinal_lymph_node_meastasis_in_patients_with_non-small_cell_lung_cancer_Comparison_with_compu [14] Knopp MV, Giesel FL, Marcos H, et al. Dynamic Contrast-Enhanced magnetic resonance imaging in oncology[J]. Top Magn Reson Imaging, 2001, 12(4): 301-8. doi: 10.1097/00002142-200108000-00006 [15] Fujimoto K, Abe T, Muller NL, et al. Small peripheral pulmonary carcinomas evaluated with dynamic Mr imaging: correlation with tumor vascularity and prognosis[J]. Radiology, 2003, 227(3): 786-93. doi: 10.1148/radiol.2273020459 [16] Stomper PC, Winston JS, Herman S, et al. Angiogenesis and dynamic Mr imaging Gadolinium enhancement of malignant and benign breast lesions[J]. Breast Cancer Res Treat, 1997, 45(1): 39-46. doi: 10.1023/A:1005897227030 [17] Ohno Y, Nogami M, Higashino T, et al. Prognostic value of dynamic Mr imaging for non-small-cell lung Cancer patients after chemoradiotherapy[J]. J Magn Reson Imaging, 2005, 21(6): 775-83. doi: 10.1002/(ISSN)1522-2586 [18] Philips TL. Radiation-chemotherapy interaction. Lung cancer principles and practice[J].Philadelphia:Lippincott-Raven. [19] Dean PB, Niemi P, Kivisaari L, et al. Comparative pharmacokinetics of Gadolinium DTPA and Gadolinium chloride [J]. Invest Radiol, 1988, 23(Suppl 1): S258-60. https://www.ncbi.nlm.nih.gov/pubmed/3198357 [20] Franklin WA. Pathology of lung cancer[J]. J Thorac Imaging, 2000, 15(1): 3-12. doi: 10.1097/00005382-200001000-00003 [21] Schaefer JF, Schneider V, Vollmar J, et al. Solitary pulmonary nodules: Association between signal characteristics in dynamic contrast enhanced MRI and tumor angiogenesis[J]. Lung Cancer, 2006, 53(1): 39-49. doi: 10.1016/j.lungcan.2006.03.010 [22] Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors[J]. J Magn Reson Imaging, 1999, 10(3): 260-6. doi: 10.1002/(ISSN)1522-2586 [23] Sommer G, Bauman G, Koenigkam-Santos M, et al. Non-contrast-enhanced preoperative assessment of lung perfusion in patients with non-small-cell lung Cancer using Fourier decomposition magnetic resonance imaging[J]. Eur J Radiol, 2013, 82(12): e879-87. doi: 10.1016/j.ejrad.2013.06.030 [24] Henschke CI, Shaham D, Farooqi A, et al. Computerized tomography screening for lung Cancer: new findings and diagnostic work-up[J]. Kyobu Geka, 2003, 15(4): 397-404. [25] Bom HS, Yc K, Song HC, et al. Technetium 99mTc-MIBI uptake in small cell lung cancer[J]. Nucl Med, 1998, 39(1): 91-4. [26] Yoshihiri N, Yukiko K, Yuka Y, et al. 99mTC-MIBI and 201TI scintigraphy of primary lung cancer[J]. J Nucl Med, 1997, 38(9): 1358-61. [27] Hendrikse NH, Kuipers F, Meijer C, et al. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein cancer [J]. Chemother Phamacol, 2004, 54(2): 131-8. doi: 10.1007/s00280-004-0793-2 [28] Kawai H, Kiura K, Tabata M, et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy[J]. Lung Cancer, 2002, 35(3): 305-14. doi: 10.1016/S0169-5002(01)00430-5 [29] Nikoletic K, Lucic S, Peter A, et al. Lung 99mTc-MIBI scintigraphy: impact on diagnosis of solitary pulmonary nodule[J]. Bosn J Basic Med Sci, 2011, 11(3): 174-9. [30] Yang ST, Zhou YZ, Zeng J. 99mTc-MIBI single-photon emission-computed tomography in diagnosis of lung cancer and mediastinal metastasis lymph nodes[J]. Zhongguo Yao Li Xue Bao, 1999, 20(9): 800-4. https://www.ncbi.nlm.nih.gov/pubmed/11245087 [31] Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2002, 54(4): 1024-35. doi: 10.1016/S0360-3016(02)03038-9 [32] Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer[J]. Ann Thorac Surg, 2004, 78(6): 1903-9; discussion 1909. doi: 10.1016/j.athoracsur.2004.06.102 [33] Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer[J]. Eur Radiol, 2009, 19(6): 1347-57. doi: 10.1007/s00330-009-1303-z [34] Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2(stage IIIa)non-small cell lung cancer after neoadjuvant chemo-radiotherapy.a prospective study[J]. J Thorac Cardiovasc Surg, 2006, 131(6): 1229-35. doi: 10.1016/j.jtcvs.2005.08.070 [35] Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy[J]. Clin Cancer Res, 2006, 12(1): 97-106. doi: 10.1158/1078-0432.CCR-05-0510 [36] Rozental JM, Levine RL, Nickles RJ, et al. Glucose-uptake by gliomas after treatment - a positron emission tomographic study[J]. Arch Neurol, 1989, 46(12): 1302-7. doi: 10.1001/archneur.1989.00520480044018 [37] De Witte O, Hildebrand J, Luxen A. et al. Acute effect of camus-tine glucose metabolism in brain and glioblastoma[J]. Cancer, 1994, 74 (10): 2836-42. doi: 10.1002/(ISSN)1097-0142 [38] Shankar LK, Hoffman M, Bacharach S, et al. Consensus recommendations for use of 18F-FDG PET as an indicator off therapeutic response in patients in National cancer Institute Trials [J]. J Nucl Med, 2006, 47(6): 1059-66. [39] Kanters LV, biologicalfactors in the prognosis of non-small cell lung cancer Eur Respira J 11, 0laussen K A DA, et al. DNA repair by ERCC1 in non-small-cell-cancer lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Eng1 J Med, 2006, 355(10): 983-91. doi: 10.1056/NEJMoa060570 [40] Niedemhofer LJ, Odijk H, Budzowska M, et al. The structure specific endonuclease Erccl-X pf is required to resolve DNAinterstrand cross-link-induced double-strand breaks [J]. Mo1CellBiol, 2004, 24(13): 5776-87. [41] Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients[J]. Clinical Cancer Research, 2005, 11(4): 1534-8. doi: 10.1158/1078-0432.CCR-04-1953 [42] Harada T, Ogura S, Yamazaki K, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers[J]. Cancer Sci, 2003, 94(4): 394-9. doi: 10.1111/cas.2003.94.issue-4 [43] Krajewska M, Turner BC, Shabaik A, et al. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers[J]. Prostate, 2006, 66(8): 801-10. doi: 10.1002/(ISSN)1097-0045 [44] Crocoll A, Schneikert J, Hubner S, et al. BAG-1M: A potential specificity determinant of corticosteroid receptor action[J]. Kidney Int, 2000, 57(4): 1265-9. doi: 10.1046/j.1523-1755.2000.00960.x [45] Boar RH, Smith IE, Pastorino U, et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung Cancer:a Smith 11,, Pastorino U.et al.Pre-operative randomized feasibility study justifying a multicentre phase III trial[J]. Br J Cancer, 1999, 79(9/ 10): 1514-8. doi: 10.1038/sj.bjc.6690241 [46] Junker KF. Grading of tumor regression in nor-small cell lung cancers[J]. Chest, 2001, 120(5): 1584-91. doi: 10.1378/chest.120.5.1584 [47] Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-85. doi: 10.1200/JCO.2007.15.0235
点击查看大图
计量
- 文章访问数: 417
- HTML全文浏览量: 201
- PDF下载量: 2
- 被引次数: 0